Resilience has spent the past year reshaping its business with a clear objective: sharpen focus, strengthen execution, and deliver with consistency. In this interview, Catherine Hanley, VP, Head of Marketing and Corporate Communications, explains how the company has rebalanced its network and aligned around its core strengths in biologics and sterile fill/finish manufacturing.

She also points to a broader shift across the CDMO landscape, where accountability, selectivity, and operational rigor are taking center stage. In this environment, Resilience is positioning itself as a dependable, long-term partner, built to meet rising expectations for performance, reliability, and scale.

Q: Resilience underwent significant changes over the past year. How would you characterize that transformation? What lessons were learned from the experience?

 A: Over the past year, Resilience has taken a deliberate and disciplined approach to simplifying and focusing the business. This included streamlining our network and concentrating our efforts on core areas where we have demonstrated strength, particularly in biologics and sterile fill/finish manufacturing.

These actions were designed to reinforce our operational foundation and ensure that our capabilities are aligned with areas of sustained industry demand and long-term relevance. While the changes were significant, they have resulted in a more centered organization with improved clarity around execution priorities.

Today, Resilience is better positioned to operate with consistency and deliver against the expectations of customers who rely on us for critical manufacturing support.

Q: Are the challenges faced by Resilience unique to this company, or are they affecting the broader industry? What distinguishes Resilience from its competitors?

 A: These challenges are not unique to our organization. They reflect broader dynamics across the CDMO and biopharmaceutical manufacturing landscape. Over the past several years, our industry has experienced rapid expansion, followed by a period of recalibration as funding environments tightened and program pipelines became more selective.

As a result, many customers are placing increased emphasis on operational excellence, available capacity, and sustainable growth. Prioritizing a CDMO that can demonstrate consistency, reliability, and long-term commitments is more critical. In that context, the actions we have taken are consistent with a broader industry shift toward focus and accountability. The differentiation lies in how effectively companies can adjust their operating model to fit those new demands for heightened accountability and reliable performance.

Resilience recommitted to focus on what it does best and renewed operational alignment across the organization. Over time, we have transitioned from a broader, more expansive model to one that is more concentrated around our core capabilities of biologics drug substance and sterile fill/finish.

Ultimately, while the underlying challenges are industry-wide, the ability to respond with clarity, discipline, quality, and consistent delivery is what distinguishes Resilience in the current environment. Resilience is now a streamlined, execution-oriented organization with a clear emphasis on reliability and long-term scalability.

Q: How do you choose and prioritize your customers’ programs?

 A: A combination of technical synergy, operational feasibility, and long-term partnership potential determines program selection. We focus on opportunities that align closely with our core capabilities and where we can support the full scope of manufacturing requirements with a high degree of confidence.

Equally important is establishing alignment with customers on key factors such as timelines, program complexity, and execution requirements. Where that alignment is not present, we take a disciplined approach and may choose not to proceed.

This level of selectivity is critical to maintaining consistent performance across our network. It ensures that the programs we take on are positioned for success and that we can meet the quality, delivery, and growth expectations of our customers.

Q: What does Resilience represent to your customers today?

A: For our customers, Resilience represents a reliable partner for the delivery of critical manufacturing supply – not only for right now, but for the future. We become an extension of their mission, goals, and team. In practice, that means consistent execution, dependable quality, the ability to support programs over the long term, and ultimately, dedication to the success of their program.

It also reflects a commitment to transparency and alignment throughout the lifecycle of a program. Clear communication and realistic planning are essential to avoiding disruptions and ensuring successful outcomes.

In an environment where supply chain reliability faces elevated expectations, our focus is providing customers with confidence that their manufacturing partner is stable, capable, and prepared to deliver when it matters most.

Q: What milestones or goals is the company focused on over the next 12 months?

A: Over the next 12 months, our priorities are centered on execution, consistency, and reinforcing confidence among our customers and partners.

First and foremost, we are focused on delivering operational excellence across our network. This includes meeting key milestones for customer programs, maintaining high standards for quality and compliance, and ensuring reliable on-time delivery. In the current environment, consistency is one of the most important indicators of stability.

Second, we are continuing to strengthen our financial position and operational rigor. The actions taken over the past year, combined with financing announced in October of 2025, have positioned the company on a solid foundation. Our focus now is on sustaining that momentum through disciplined growth and careful resource allocation.

Third, we are advancing programs within our core areas, particularly in aseptic fill/finish, biologics, and cell therapy manufacturing. This includes supporting customers as their programs progress through clinical development and, where applicable, toward commercialization. Demonstrating the ability to scale alongside our customers is a key objective.

We are also investing in the customer experience to ensure clear communication, transparency, and alignment throughout the lifecycle of each program. These elements are critical to building long-term partnerships and differentiating in a competitive CDMO landscape.

Collectively, these priorities reflect a broader goal: to demonstrate, through measurable performance, that Resilience is a dependable, execution-focused partner capable of supporting critical manufacturing needs over the long term.

Q: Where do you see the market heading over the next few years?

A: Over the next several years, we expect the CDMO market to continue shifting toward greater focus, discipline, and selectivity. Following a period of rapid expansion and condensed timelines, the industry is entering a phase where the pace of change is accelerating; funding is more constrained, and CDMOs are held to increasingly rigorous standards.

We expect to see continued prioritization of high-value modalities, particularly in biologics and cell therapies, alongside increased demand for partners that can support multiple program components in a single location. At the same time, customers are becoming more selective, placing greater emphasis on consistent delivery through reliable automation, established quality records, and predictable execution they can come to rely on. There will also likely be ongoing consolidation and rationalization across the sector, as organizations align capacity with demand and focus on core strengths. This environment will favor CDMOs that demonstrate clear strategic direction, financial stability, and a track record of delivery.

From a customer perspective, the bar is rising. Manufacturing is increasingly viewed not just as a service, but as an investment in program success. As a result, long-term partnerships built on transparency, performance, trust, and a unified pursuit of success will become even more important.

Overall, the market is moving toward a more disciplined and performance-driven model, where reliability and the ability to deliver consistently will be key differentiators.